- 86% complete remission rate with 71% of patients achieving negative minimal residual disease status with a sub-therapeutic dose of Actimab-A with CLAG-M in second dose cohort of early stage safety trial
- Preliminary remission rates achieved with Actimab-A combined with CLAG-M compare favorably to targeted agents recently approved for patients with relapsed or refractory AML
PR Newswire
NEW YORK, March 5, 2020